Aurobindo Pharma informs about disclosure
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from December 08 to December 17, 2025. At the end of the inspection, a ‘Form 483’ was issued with 05 observations. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (VAI) and this inspection is now ‘closed’.
The above information is a part of company’s filings submitted to BSE.
